New Arm Rehabilitation Device for Stroke Patients Developed

Tailwind Logo-215 Orthometrix acquires exclusive worldwide rights from Encore Path to market the Tailwind™ Arm Rehabilitation device developed at the University of Maryland, Baltimore

tailwind arm equipNAPLES, FL, JULY 8, 2014 — ORTHOMETRIX, INC. announced today that it has signed an exclusive agreement with ENCORE PATH, INC. to market, sell and service worldwide the Tailwind™ arm rehabilitation device. The Tailwind™ is a patented Bilateral Arm Trainer with Rhythmic Auditory Cueing (BATRAC) that was developed at the University of Maryland School of Medicine’s Department of Physical Therapy and Rehabilitation Services and licensed to Encore Path, Inc., a portfolio company of the New Ventures Department of the University of Maryland, Baltimore. The Tailwind has been shown to improve arm movement in stroke patients with paralysis. It will be initially marketed in Asia and in Israel, and then in the U.S. after a Centers for Medicare & Medicaid Services (CMS) HCPCS code is obtained for use of the Tailwind as a durable medical equipment (DME).

Commenting on this agreement, Reynald Bonmati, Chairman and Chief Executive Officer of Orthometrix, stated, “I am very pleased to partner with Encore Path and the University of Maryland. The Tailwind™ for upper-limb rehabilitation of stroke patients is a natural addition to our SmartStep® Biofeedback system for lower-limb rehabilitation, developed and manufactured by our partner Andante Medical Devices, Inc. Orthometrix, Andante and Encore Path are currently working on the manufacturing of the Tailwind™ by Andante.

man using arm rehab tailwindThe Tailwind was developed by physicians from the University of Maryland specializing in physical therapy and rehabilitation after a decade of scientific research. Clinical studies have shown that the device helps improve arm mobility, function, and range of motion in patients with even severe paralysis. Representatives from the University of Maryland’s New Ventures Department facilitated the introduction of Encore Path, Inc. and Orthometrix, Inc. and the subsequent agreement. The University of Maryland Ventures is designed to fuel the growth of the University’s startups, particularly those based upon intellectual property developed by physicians at the University of Maryland, Baltimore and University of Maryland, College Park.

Encore Path, Inc. is a Baltimore, Maryland-based medical device company that was founded in 2006 by entrepreneur Kris Appel to develop devices and therapies that will improve the quality of life for stroke survivors and their families. The Tailwind, Encore Path’s debut product, is already in use throughout the United States and on five continents. Our Web address is

Orthometrix, Inc. markets, sells and services several musculoskeletal product lines used in research, diagnostic and monitoring of bone and muscle disorders; and for therapy in sports medicine, rehabilitative medicine, physical therapy, orthopedic and neurological trauma, pain management, fitness and wellness (pQCT™, Oscar, Jr.™ DXA phantom, Galileo™, VibraFlex®, Leonardo™, SmartStep®, Tailwind™ and Orbasone™ ESWT pain management system). Our Web address is The Websites dedicated to our main products are (VibraFlex®); (SmartStep®); (Tailwind™).

Media contacts:

Orthometrix, Inc.
Reynald Bonmati, President
Encore Path, Inc.
Kris Appel, President
University of Maryland Ventures
Linda Cassard

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this release are forward looking statements that involve risk and uncertainties, including, but not limited to, any effect on future financial results from efforts to broaden the Company’s position in the musculoskeletal devices and medical devices business, any potential impact on sales of the pQCT® systems and Oscar, Jr. DXA phantom for bone & muscle research and diagnostic, any potential impact on sales of the Galileo™, VibraFlex®, SmartStep®, Leonardo™, Tailwind™ and Orbasone™ ESWT electrodes for rehabilitation, physical therapy, sports, fitness, wellness and pain management in the hospital, clinic or at home, and other risks. These risks and uncertainties could cause actual results to differ materially from those expected and/or contained in the forward-looking statements. Any forward-looking statement made in this release is made as of the date of this release and the Company assumes no obligation, subject to applicable law, to update such forward-looking statement.

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in In The News, Press Releases, Primary Care and tagged , . Volume: .

Post a Comment

You must be logged in to post a comment.